1 / 17

A science-led global healthcare company with a special purpose

A science-led global healthcare company with a special purpose. HIV virus. Who we are. A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

hamilton
Télécharger la présentation

A science-led global healthcare company with a special purpose

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A science-led global healthcare company with a special purpose HIV virus

  2. Who we are A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have 3 global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.

  3. Our goal is to be one of the world’s most innovative, best performing and trusted healthcare companies. Bhupal Senior Scientist, UK

  4. What we do We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our 3 global businesses, scientific and technical know-how and talented people. Our goal is to be one of the world’s most innovative, best performing and trusted healthcare companies. 8.9bnpacks/doses of medicines, vaccines and healthcare products produced in 2017 Angie, Consumer, UK

  5. Pharmaceuticals Our Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in respiratory and HIV. Our R&D approach focuses on science related to the immune system, use of genetics and advanced technologies. £17.3bn Sales turnover 2017 Immune system T-cells attacking a cancer cell

  6. Vaccines Our Vaccines business has a broad portfolio and innovative pipeline of vaccines to help protect people throughout life. We deliver over two million vaccine doses per day to people living in over 160 countries. £5.2bn Sales turnover 2017 Herpes zoster virus of shingles

  7. Consumer Healthcare Our Consumer Healthcare business develops and markets an innovative portfolio of consumer preferred and expert recommended brands in the Oral health, Pain relief, Respiratory, Skin health, Nutrition and Digestive categories. £7.8bn Sales turnover 2017 Novamin, a key technology in Sensodyne Repair and Protect

  8. How we do it Everyone at GSK is focused on 3 priorities: Innovation Performance Trust Hoi-Kei Quality Assurance, Singapore

  9. Our long-term priorities Innovation We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers. 3major launches in 2017 – Shingrix, a vaccine for shingles, Trelegy Ellipta for COPD and Juluca for HIV £3.9bn R&D investment in 2017 27immunomodulatory new molecular entities in the pipeline for a range of diseases  11,000people working in R&D around the world

  10. In 2018 GSK announced a new collaboration with 23andMe, to develop innovative new medicines and potential cures, using human genetics as the basis for discovery. Rodrigo, Cell Transduction Scientist, UK

  11. Our long-term priorities Performance We aim to achieve industry-leading growth by investing effectively in our business, developing our people and delivering flawlessly. £30.2bntotal turnover in 2017 No.1dolutegravir is the most prescribed core agent for HIV treatments worldwide >£1bnSensodyne sales – world’s number one dentist recommended toothpaste for sensitive teeth >100mEllipta inhalers produced to treat asthma and COPD

  12. Around 40% of the world’s children are protected with at least one GSK vaccine.  Two million doses of our vaccines are delivered to 160 countries per day. Alexia, Patient, Belgium

  13. Our long-term priorities Trust We are a responsible company and commit to use our science and technology to address health needs, make our products affordable and available and to be a modern employer. 119,000of our people and their families in 93 countries have access to healthcare with our Partnership for Prevention programme 1stcandidate vaccine showing efficacy against malaria and 1st single dose medicine to treat relapsing malaria 1stin class medicines in pipeline and a much needed candidate vaccine to help fight tuberculosis 84%of employees are proud to work for GSK

  14. Our approach to global health focusses our science on three of the biggest health challenges affecting children and young people in the developing world – HIV, TB and Malaria. Each year 6 million children under the age of five die from preventable causes, in developing countries. Eva, Scientist, Spain

  15. Our values and expectations Our values and expectations are at the heart of everything we do and help define our culture – so that together we can deliver extraordinary things for our patients and consumers and make GSK a brilliant place to work.

  16. A great example of how we live our values and expectations is our partnership with Save the Children. We have reached over 2.8 million children in 45 countries, and GSK employees have raised over £3.3mwhich is matched by GSK. GSK employees, Egypt

  17. Why we do it To help people do more, feel better, live longer. Jaden, Jo, Alan, Michelle and Jenna,UK

More Related